Explore inhalation API reformulation, low-GWP propellants, and particle engineering challenges driving sustainable respiratory drug development. Includes market growth insights and regulatory trends shaping next-gen inhalation therapies. Introduction: The respiratory drug delivery field is undergoing a significant transformation as pharmaceutical companies…
If you are comparing HFO-1234ze vs HFA-152a, the right choice depends on your formulation strategy, device requirements, safety controls, and environmental goals. Both are promising options as low-GWP propellants for pMDIs, but they differ in flammability, solvency, density, and regulatory…
The Drug Delivery to the Lungs Conference (DDL) is in it’s 34th year and attracts in excess of 1000 attendees worldwide, including scientists, academics, clinicians, regulators and industry experts. The conference includes a large industry exhibition, supported by over 100…
Cardiff, UK, Press Release 26th June 2024 Cardiff Scintigraphics has appointed John Pritchard as the new Chairman of the Board of Directors with effect from 27th June 2024. John will be succeeding Dr David Owen who will be stepping down…
Cardiff, UK, Press Release 30 May 2024 Cardiff Scintigraphics has appointed Andrew Brown as the new Chief Executive Officer and member of the Board of Directors, with effect from 03 June 2024. Andrew will be succeeding Glyn Taylor who will…
DDL attracts a wide variety of attendees, including scientists, academics, clinicians, regulators and industry experts. DDL offers the opportunity for lectures, posters and exhibitions to be closely located thereby enhancing interactions and networking opportunities for attendees, presenters and exhibitors. DDL…